Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05461209 Withdrawn - Clinical trials for Relapsed/ Refractory Multiple Myeloma

A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma

MonumenTAL-5
Start date: October 20, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).

NCT ID: NCT05456269 Withdrawn - Clinical trials for Acute Myeloid Leukemia

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS

BISECT
Start date: July 29, 2022
Phase: Phase 1
Study type: Interventional

This is a two strata Phase 1b study to assess the safety and efficacy of bisantrene (RC110) in combination with a) cytarabine arabinoside (Ara-C) treatment for patients with relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) with extramedullary disease and able to tolerate intensive chemotherapy; b) in combination with decitabine/cedazuridune (ASTX727) new or relapsed or refractory AML or high risk MDS or CMML with extramedullary disease and unable or not willing to have intensive chemotherapy.

NCT ID: NCT05442762 Withdrawn - Machine Learning Clinical Trials

Social Media-based Vaccine Confidence and Hesitancy Monitoring

Start date: March 1, 2022
Phase:
Study type: Observational

History and scientific evidence show that it is critical to maintain public trust and confidence in vaccination. Any crisis in confidence has the potential to cause significant disruption and a detrimental impact on vaccination. Vaccine hesitancy is a complex and context-specific issue that varies across time, place, and vaccines. It has been cited by World Health Organization(WHO) as one of the top ten threats to global health in 2019. Coronavirus disease(COVID-19) pandemic may change public confidence in vaccines. Therefore, it is necessary to establish a surveillance system to monitor vaccine confidence and hesitancy in real time. To date, a growing body of literature has used social media platforms such as Twitter and weico for public health research. Large amounts of real time data posted on social media platforms can be used to quickly identify the public's attitudes on vaccines, as a way to support health communication and health promotion, messaging. However, textual data on social media is difficult to be analyzed. Recent progress in machine learning makes it possible to automatically analyze textual data on social media in real time. In this study, the investigators will establish a social media surveillance and analysis platform on vaccines, develop a series of machine learning models to monitor vaccine confidence and early detect emerging vaccine-related risks, and assess public communication around vaccines. The investigators will assess the temporal and spatial distribution of vaccine confidence and hesitancy globally using Twitter data and in China using weico data, for all vaccines and Human Papilloma Virus(HPV) vaccine, respectively. Our study will guide the design of effective health communication strategies to improve vaccine confidence.

NCT ID: NCT05438758 Withdrawn - Clinical trials for Treatment Resistant Major Depressive Disorder

Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study

ZYL-730-02
Start date: January 15, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if any improvements in depressive symptoms are maintained in the medium and longer-term (up to 3 months)

NCT ID: NCT05416320 Withdrawn - Clinical trials for Central Centrifugal Cicatricial Alopecia

Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

CCCA
Start date: August 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this pilot study is to determine if calcipotriol shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). This study aims to evaluate calcipotriol due to the possible anti-inflammatory effects that may affect the hair growth cycle.

NCT ID: NCT05412875 Withdrawn - Clinical trials for Head and Neck Squamous Cell Carcinoma

Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This clinical trial investigates the acceptability of electronic cigarettes (JUUL) for smoking cessation (quitting smoking) and the reduction of surgery-related complications in patients with newly diagnosed head, neck, or lung cancer. Smoking before surgery is associated with increased risk of complications during and after surgery. Electronic cigarettes are a type of special product that gives small, steady doses of nicotine to help stop cravings and relieve symptoms that occur when a person is trying to quit smoking. Stopping cigarette smoking before surgery may reduce the risk of complications during and after surgery in patients with head, neck, or lung cancer.

NCT ID: NCT05408026 Withdrawn - Clinical trials for Relapsed or Refractory Multiple Myeloma

Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

Start date: October 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase II clinical trial design with a safety run-in period will be used to assess the rate of VGPR or better for the combination PVD-Dara in the treatment of RRMM.

NCT ID: NCT05405686 Withdrawn - Clinical trials for Poor Response to Ovulation Induction

Effect of LH Supplementation on the Endometrial Gene Expression Profile in Poor Ovarian Responders

Start date: May 1, 2023
Phase: Phase 4
Study type: Interventional

This is a prospective randomized open-label cross-over study. Poor responder patients will undergo two ovarian stimulation cycles. One with recombinant follicle stimulation hormone (FSH), and an other stimulation with recombinant FSH and recombinant luteinizing hormone (LH). In both groups, a freeze-all strategy will be applied and an endometrial biopsy will be taken 7 days after final oocyte maturation trigger. Endometrial gene expression analysis will be performed on both biopsies. After completion of both treatment cycles, a frozen embryo transfer of a single embryo will be performed.

NCT ID: NCT05405192 Withdrawn - Clinical trials for Gestational Trophoblastic Neoplasia

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if Dostarlimab is an effective treatment for Gestational Trophoblastic Neoplasia (GTN).

NCT ID: NCT05403580 Withdrawn - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer

Start date: June 3, 2022
Phase: Phase 3
Study type: Interventional

This phase III trial compares olanzapine to placebo in decreasing nausea and vomiting in patients with cancer that has spread to other places in the body (advanced). Patients with advanced cancer may experience nausea and/or vomiting that is unrelated to chemotherapy or radiation. Giving olanzapine may help reduce nausea and increase appetite in patients who have advanced cancer.